Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Exploring the current treatment landscape in the melanoma space, including IOVA's LN-144, with a specific focus on the checkpoint refractory population

Ticker(s): IOVA

Who's the expert?

Name: Dr Sanjiv Agarwala - MD

Institution: St. Luke's Cancer Center | Temple University

  • Chairman of Medical Oncology, Professor & Chief Hematology & Oncology St Luke’s Cancer Center & Temple University.
  • Currently manages ~100 patients with melanoma.
  • Internationally recognized investigator in the field of melanoma and immunotherapy; has led several clinical trials of immunotherapy and targeted therapy in melanoma. 

Interview Questions
Q1.

Please describe your clinical practice; roughly how many patients with melanoma do you currently manage?

Added By: c_admin
Q2.

What is your current first line therapy in treating melanoma?

Added By: c_admin
Q3.

What are your thoughts on the potential for TIL therapies in this disease?

Added By: c_admin
Q4.

Can you please discuss the specific needs of the checkpoint refractory population.

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.